Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
Abeona Therapeutics Inc. (ABEO) stock rallied over 4.00% intraday to trade at $0.21 a share on NASDAQ. The stock opened with a gain of 10.53% at $0.201 and touched an intraday high of $0.208, rising 5.00% against the last close of $0.2. The stock went to a low of $0.188 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $0.201 | $0.208 | $0.188 | $0.208 | 1,867,529 |
2022-06-29 | $0.19 | $0.21 | $0.18 | $0.2 | 2,310,100 |
2022-06-28 | $0.18 | $0.2 | $0.18 | $0.18 | 2,815,500 |
2022-06-27 | $0.17 | $0.19 | $0.17 | $0.18 | 1,415,500 |
2022-06-24 | $0.19 | $0.2 | $0.17 | $0.17 | 1,670,700 |
2022-06-23 | $0.17 | $0.19 | $0.16 | $0.19 | 2,572,700 |
2022-06-22 | $0.18 | $0.18 | $0.16 | $0.17 | 1,613,600 |
2022-06-21 | $0.16 | $0.18 | $0.16 | $0.17 | 3,239,200 |
2022-06-17 | $0.16 | $0.17 | $0.15 | $0.16 | 1,591,600 |
2022-06-16 | $0.16 | $0.16 | $0.15 | $0.16 | 1,088,200 |
Employees-
Beta1.33
Sales or Revenue3 Million
5Y Sales Change27.50%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Abeona Therapeutics Inc. (NASDAQ: ABEO) stock price is $0.21 as of the last check on Thursday, June 30. During the trading session, ABEO stock reached the peak price of $0.208 while $0.188 was the lowest point it dropped to.
The NASDAQ listed ABEO is part of Biotechnology industry that operates in the broader Health Care sector. Abeona Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases.
Mr. Edward G. Carr
Sr. VP, CFO & Chief Accounting Officer
Dr. Vishwas Seshadri M.B.A., Ph.D.
CEO & Director
Mr. Brian Kevany Ph.D.
VP & Chief Technical Officer
Sofia Warner
Sr. Director of Investor Relations
ABEO stock traded closed the last session at $0.208, which is $0.01 or 4.00% lower than its previous close of $0.2. ABEO's current trading price is 59.63% lower than its 52-week high of $1.63 where as its distance from 52-week low of 0.13% is -87.24%.
Number of ABEO employees currently stands at -. ABEO operates from 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019, United States.
Official Webiste of $ABEO is: https://www.abeonatherapeutics.com
ABEO could be contacted at ABEO operates from 1330 Avenue of the Americas, 33rd Floor, New York, NY 10019, United States, or at phone #646 813 4701 and can also be accessed through its website.
ABEO stock volume for the day was 1,979,645 shares while in the previous session number of ABEO shares traded was 1,867,529 . The average number of ABEO shares traded daily for last 3 months was 1.95 Million.
The percentage change in ABEO stock occurred in the recent session was 4.00% while the dollar amount for the price change in ABEO stock was $0.01.
In the recent session, the day high for ABEO stock was $0.208 while the low for ABEO stock touched on the day was $0.188.
The market value of ABEO currently stands at 32.24 Million with its latest stock price at $0.21 and 144.88 Million of its shares outstanding.